A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2014
Price : $35 *
At a glance
- Drugs AMG 333 (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 08 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Nov 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
- 04 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.